VWF and thrombotic thrombocytopenic purpura: The correlation between vWF and platelets and the vWF/platelet ratio might also suggest that targeting this axis with caplacizimab is now used in the treatment of thrombotic thrombocytopenic purpura (TTP) may be of benefit [24].